OPKO Health (OPK)
(Delayed Data from NSDQ)
$1.51 USD
0.00 (0.00%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $1.52 +0.01 (0.66%) 7:58 PM ET
2-Buy of 5 2
C Value D Growth D Momentum F VGM
Price, Consensus and EPS Surprise
OPK 1.51 0.00(0.00%)
Will OPK be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for OPK based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for OPK
Waters (WAT) Beats Q3 Earnings and Revenue Estimates
OPK Gets Additional BARDA Funding to Develop Multispecific Antibodies
OPK: What are Zacks experts saying now?
Zacks Private Portfolio Services
Here's Why You Should Retain OPKO Health Stock in Your Portfolio
ENTX & OPK Stock May Gain Following Positive PK/PD Research Data
OPKO Health (OPK) Q2 Earnings Top Estimates, Gross Margin Down
Other News for OPK
NextPlat gets four-year extension of OPKO Healthcare e-commerce program in China
ModeX secures $35M BARDA supplement to develop COVID antibodies
Entera Bio and OPKO Health Provide Update on PK/PD Results of Oral Oxyntomodulin (GLP-1/Glucagon) Peptide Tablet Candidate for Obesity and Metabolic Disorders
OPKO Health?s ModeX Therapeutics Appoints Dr. Giovanni Abbadessa as Chief Medical Officer as Pipeline Advances into Clinical Development
Greenberg Traurig Advises OPKO Health in $237.5 Million Asset Sale to Labcorp